slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 25,351-25,380
Pages 1,349
Rows per page 30
Beat
25,351-25,380 of 40,452
23
Genius Group | Investor Presentation Deck | 29 slidesGenius Group | Investor Presentation Deck | 29 slides · Genius Group
Pitch deck Investor relations Beat · Financials1 hit
24
Genius Group | Investor Presentation Deck | 29 slidesGenius Group | Investor Presentation Deck | 29 slides · Genius Group
Pitch deck Investor relations Beat · Financials1 hit
25
Genius Group | Investor Presentation Deck | 29 slidesGenius Group | Investor Presentation Deck | 29 slides · Genius Group
Pitch deck Investor relations Beat · Financials1 hit
26
The table includes both audited and unaudited financial data, with a specific note defining the calculation methodology for Adjusted EBITDA.Genius Group | Investor Presentation Deck | 29 slides · Genius Group
Pitch deck Investor relations Beat · Financials1 hit
27
Genius Group | Investor Presentation Deck | 29 slidesGenius Group | Investor Presentation Deck | 29 slides · Genius Group
Pitch deck Investor relations Beat · Financials1 hit
28
The slide includes a specific definition of Adjusted EBITDA in the footer.Genius Group | Investor Presentation Deck | 29 slides · Genius Group
Pitch deck Investor relations Beat · Financials1 hit
04
The chart uses imagery within the donut segments to represent the two sectors.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · ProblemLoop · Mece Breakdown1 hit
05
GMS | Investor Conference Presentation Deck | 26 slidesGMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · ProblemLoop · Voice Of Customer1 hit
10
Uses a combination of a pie chart with a callout segment and two donut charts to illustrate portfolio shift.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
11
The slide uses a table to categorize recent expansions into acquisitions and greenfield openings.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
12
The slide highlights whitespace and underpenetrated markets in the US and Canada.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
13
Includes financial metrics for GMS Inc. as of 7/31/23.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
14
GMS | Investor Conference Presentation Deck | 26 slidesGMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
15
GMS | Investor Conference Presentation Deck | 26 slidesGMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
16
GMS | Investor Conference Presentation Deck | 26 slidesGMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
17
Includes footnotes regarding Adjusted EBITDA, Free Cash Flow, and Tax Rate.GMS | Investor Conference Presentation Deck | 26 slides · GMS
Conference presentation Investor relations Beat · Financials1 hit
15
Slide 14 of the deck.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · DesireLoop · Golden Circle1 hit
16
Includes a specific callout to Goldman Sachs forecasts as the source for growth data.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · DesireLoop · Golden Circle1 hit
07
The table uses a traffic light system (green, yellow, red) to visually indicate performance across categories.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Market Size1 hit
08
The slide uses a comparison framework to contrast traditional vs. new product workflows.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Market Size1 hit
19
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Team1 hit
28
The chart illustrates deepening responses over time in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
31
Includes FDA approval precedents in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
32
The diagram illustrates a classic dose-escalation study design.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
33
The slide uses a mix of expert quotes and a comparative table of clinical trials to validate the outpatient therapy thesis.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
34
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
35
Includes scientific diagrams of molecular pathways and efficacy charts.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
36
Slide contains three distinct data visualizations comparing IMX-110 against standard of care or historical benchmarks.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit